Eiger BioPharmaceuticals Statistics
Total Valuation
Eiger BioPharmaceuticals has a market cap or net worth of 12.59 million. The enterprise value is -19.14 million.
| Market Cap | 12.59M |
| Enterprise Value | -19.14M |
Important Dates
The last earnings date was Friday, November 1, 2024.
| Earnings Date | Nov 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Eiger BioPharmaceuticals has 1.48 million shares outstanding. The number of shares has increased by 6.39% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.48M |
| Shares Change (YoY) | +6.39% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 16.96% |
| Owned by Institutions (%) | 10.05% |
| Float | 1.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.80 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.26 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.26 |
Financial Position
The company has a current ratio of 0.71
| Current Ratio | 0.71 |
| Quick Ratio | 0.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.55 |
| Interest Coverage | -13.13 |
Financial Efficiency
Return on equity (ROE) is -367.00% and return on invested capital (ROIC) is -73.40%.
| Return on Equity (ROE) | -367.00% |
| Return on Assets (ROA) | -56.45% |
| Return on Capital (ROIC) | -73.40% |
| Revenue Per Employee | 630,920 |
| Profits Per Employee | -3.00M |
| Employee Count | 25 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.10% in the last 52 weeks. The beta is 2.78, so Eiger BioPharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.78 |
| 52-Week Price Change | -7.10% |
| 50-Day Moving Average | 10.63 |
| 200-Day Moving Average | 6.93 |
| Relative Strength Index (RSI) | 34.90 |
| Average Volume (20 Days) | 1,124 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.10 |
Income Statement
In the last 12 months, Eiger BioPharmaceuticals had revenue of 15.77 million and -74.96 million in losses. Loss per share was -50.78.
| Revenue | 15.77M |
| Gross Profit | 15.75M |
| Operating Income | -71.79M |
| Pretax Income | -74.96M |
| Net Income | -74.96M |
| EBITDA | -71.51M |
| EBIT | -71.79M |
| Loss Per Share | -50.78 |
Balance Sheet
The company has 25.84 million in cash and 41.20 million in debt, giving a net cash position of -15.36 million or -10.37 per share.
| Cash & Cash Equivalents | 25.84M |
| Total Debt | 41.20M |
| Net Cash | -15.36M |
| Net Cash Per Share | -10.37 |
| Equity (Book Value) | -14.46M |
| Book Value Per Share | -9.77 |
| Working Capital | -15.45M |
Cash Flow
In the last 12 months, operating cash flow was -74.55 million and capital expenditures -234,000, giving a free cash flow of -74.78 million.
| Operating Cash Flow | -74.55M |
| Capital Expenditures | -234,000 |
| Free Cash Flow | -74.78M |
| FCF Per Share | -50.50 |
Margins
| Gross Margin | 99.85% |
| Operating Margin | -455.12% |
| Pretax Margin | -475.22% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -474.11% |
Dividends & Yields
Eiger BioPharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.39% |
| Shareholder Yield | -6.39% |
| Earnings Yield | -597.41% |
| FCF Yield | -594.13% |
Stock Splits
The last stock split was on January 8, 2024. It was a reverse split with a ratio of 0.0333333.
| Last Split Date | Jan 8, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0333333 |
Scores
Eiger BioPharmaceuticals has an Altman Z-Score of -24.2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -24.2 |
| Piotroski F-Score | n/a |